SCHEMBL3973638

SCHEMBL3973638

CCOC(=O)c1occ(-c2cccc(OCc3c(C)c(C)cc(C)c3C)c2)c1-c1ccccc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FABP3 P05413 1/20 0.43
FABP4 P15090 1/20 0.43
FABP5 Q01469 1/20 0.43
MAPT P10636 3/20 0.40
HPGD P15428 3/20 0.40
GAA P10253 2/20 0.40
KDM4E B2RXH2 2/20 0.40
ALDH1A1 P00352 2/20 0.40
PPARG P37231 1/20 0.40
NPC1 O15118 1/20 0.40
LMNA P02545 1/20 0.40
RAB9A P51151 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
JAK2 O60674 1/20 0.39
JAK3 P52333 1/20 0.39
PTGER4 P35408 1/20 0.39
FFAR1 O14842 2/20 0.39
L3MBTL1 Q9Y468 1/20 0.37
TSHR P16473 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3982728 0.96 MAPT (0.41) FABP3FABP4FABP5MAPTHPGD
SCHEMBL3980972 0.96 FFAR1 (0.40) FABP3FABP4FABP5MAPTHPGD
SCHEMBL28752668 0.90 PTGER4 (0.44) FABP3FABP4FABP5PTGER4FFAR1
SCHEMBL3982596 0.89 PPARG (0.51) FABP3FABP4FABP5MAPTPPARG
SCHEMBL3978466 0.87 PPARG (0.51) MAPTPPARGJAK2JAK3PTGER4
SCHEMBL3979293 0.86 FABP3 (0.41) FABP3FABP4FABP5MAPTNPC1
SCHEMBL27605311 0.85 PTGER4 (0.44) FABP3FABP4FABP5PTGER4FFAR1
SCHEMBL3982581 0.85 PPARG (0.51) MAPTGAAPPARGJAK2JAK3
SCHEMBL3979268 0.82 FFAR1 (0.43) PTGER4FFAR1CD274
SCHEMBL3973642 0.82 MAPT (0.46) MAPTHPGDGAAKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7514452-B2 2-furancarboxylic acid hydrazides and pharmaceutical compositions containing the same DAINIPPON PHARMACEUTICAL CO., LTD (JP) 2009-04-07 US disclosed
US-20050171196-A1 2-Furancarboxylic acid hydrazides and pharmaceutical compositions containing the same DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2005-08-04 US disclosed
EP-1489077-A1 2-FURANCARBOXYLIC ACID HYDRAZIDES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME DAINIPPON PHARMACEUTICAL CO., LTD. (JP) 2004-12-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050171196-A1 2-Furancarboxylic acid hydrazides and pharmaceutical compositions containing the same GLP1R, GCGR, GPR119 FABP3 1207/4885FABP4 1815/4885FABP5 1809/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.